Our COVID-19 safety protocols include universal screening, mandatory use of masks, physical distancing, and a strict no-visitor policy with exceptions only for medical necessity and pediatric patients under 18. To learn more about what we are doing to keep everyone safe during an in-office visit, click here.

Living Well

Clinical Trial: Colchicine for Early COVID-19

Last updated: Jun 16, 2020


SMG patients with active COVID-19 infection can participate in a clinical research study being led by New York University and the Montreal Heart Institute and supervised at SMG by Dr. Lauren Kennish (Rheumatology).  Colchicine is an anti-inflammatory drug that is used to treat other inflammatory conditions, such as gout. COVID-19 can cause people to get severely ill partly due to the body’s overly robust immune response to the virus. Colchicine dampens some parts of that type of immune response. The study’s goal is to determine whether short-term treatment with colchicine reduces the need for hospitalization, lung complication requiring mechanical ventilation and death related to COVID-19.

Click here for PDF version

 

NAVIGATION WE ARE HERE TO HELP YOU! STAY CONNECTED Like Tweet Watch Share Follow Instagram